Open Access

CXCL9 promotes prostate cancer progression through inhibition of cytokines from T cells

  • Authors:
    • Shanfeng Tan
    • Kai Wang
    • Fuguang Sun
    • Yang Li
    • Yisheng Gao
  • View Affiliations

  • Published online on: June 11, 2018     https://doi.org/10.3892/mmr.2018.9152
  • Pages: 1305-1310
  • Copyright: © Tan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Chemokines have been demonstrated to serve an important role in a variety of diseases, particularly in tumor progression. There have been numerous studies that have reported that T cells serve major roles in tumor progression. However, the function of CXC motif chemokine ligand 9 (CXCL9) in prostate cancer remains unknown. The present study aimed to investigate the role of CXCL9 in prostate cancer. A prostate cancer mouse model was generated by treating C57/BL‑6 and B6.Cg‑Selplgtm1Fur/J mice with 3,2'‑dimethyl 4‑aminobiphenyl (DMAB). Hematoxylin and eosin staining detected the histopathological alterations of mouse prostate tissues. Immunohistochemistry (IHC) staining determined cell proliferation of the mice. Flow cytometry was used to detect the alterations of T cells in C57+DMAB or CXCL9+DMAB mice. Immunofluorescence revealed that there was positive expression of interleukin‑6 (IL‑6) and transforming growth factor (TGF)‑β in the mouse tissues. The survival rates of C57+DMAB and CXCL9+DMAB mice was analyzed. The association of CXCL9 expression and clinical stages was also evaluated. Results revealed that prostate cancer pathology and cell proliferation in CXCL9+DMAB mice were significantly greater compared with the C57+DMAB mice. Compared with C57+DMAB mice, the number of T cells in peripheral blood and spleen of CXCL9+DMAB mice was significantly reduced. IHC demonstrated that the expression of IL‑6 and TGF‑β was significantly downregulated in the CXCL9+DMAB mice. The survival rate of CXCL9+DMAB mice was significantly decreased compared with the C57+DMAB mice. In addition, reverse transcription‑quantitative polymerase chain reaction analysis demonstrated that CXCL9 mRNA expression in clinical samples was positively associated with clinical pathological stages of prostate cancer. In conclusion, CXCL9 may promote prostate cancer progression via inhibition of cytokines from T cells.
View Figures
View References

Related Articles

Journal Cover

August-2018
Volume 18 Issue 2

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Tan S, Wang K, Sun F, Li Y and Gao Y: CXCL9 promotes prostate cancer progression through inhibition of cytokines from T cells. Mol Med Rep 18: 1305-1310, 2018.
APA
Tan, S., Wang, K., Sun, F., Li, Y., & Gao, Y. (2018). CXCL9 promotes prostate cancer progression through inhibition of cytokines from T cells. Molecular Medicine Reports, 18, 1305-1310. https://doi.org/10.3892/mmr.2018.9152
MLA
Tan, S., Wang, K., Sun, F., Li, Y., Gao, Y."CXCL9 promotes prostate cancer progression through inhibition of cytokines from T cells". Molecular Medicine Reports 18.2 (2018): 1305-1310.
Chicago
Tan, S., Wang, K., Sun, F., Li, Y., Gao, Y."CXCL9 promotes prostate cancer progression through inhibition of cytokines from T cells". Molecular Medicine Reports 18, no. 2 (2018): 1305-1310. https://doi.org/10.3892/mmr.2018.9152